New Search

If you are not happy with the results below please do another search

330 search results for:

229

Ministry of Health wants to legalize prescription of drugs off label

The Ministry of Health of the Russian Federation wants to allow doctors to prescribe medicines to patients not on instructions (off label). However, the decision to prescribe the drug can be taken only if it is approved by the medical commission. The department informed on the beginning of the development of the document “On Amending…

230

Serious changes in Stada

After failing to win the shareholder support needed to complete a €5.32 billion buyout, Stada is changing key executives. The German firm announced the resignations of CEO Matthias Wiedenfels and CFO Helmut Kraft after the board meeting on Tuesday and soon appointed new management. A former Boehringer Ingelheim exec, Engelbert Coster Tjeenk Willink will serve…

231

Bibliometric Wars

Errors in bibliographic citations are very frequent in medical articles. Although such errors may seem not important, they lower citation index of articles, affecting recognition and professional advancement of an academician. Researchers from New York University Langone Medical Center conducted analysis to highlight inaccurate and inconsistent bibliometric reports across databases. Authors searched listings of 1469…

232

Pharm community is not yet ready for union EurAsEC market

The Head of the Association of the Russian pharmaceutical manufacturers, Viktor Dmitriev, speaking at the meeting of the Integration Council of the Russian Union of Industrialists and Entrepreneurs, claimed that “The documents have been signed, but so far the union pharmaceutical market works only on paper. Unfortunately, in the nearest future we do not expect…

233

FDA’s racking up drug approvals lickety-split

By mid-2017, the FDA approved a record number of drugs that have sales firepower and one very high price. Friday’s approval for anticoagulant Bevyxxa has already become 23 in this year, exceeding the number of approvals for the entire 2016, which, according to agency statistics, was 22. Other recent approvals include such drugs as Baxdela…

234

Russia reduced spending on cancer drugs in a rapidly rising price

Russia has long been considered the main market for Western biopharma companies, which are in search of new sources of growth. And that is why every company from Pfizer to AstraZeneca called for compliance with President Vladimir Putin’s demand that Western companies join forces with local producers and establish manufacturing plants on the territory of…